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Oxaliplatin-induced peripheral neuropathy characterized especially as cold dysesthesia is a major dose-
limiting side effect of the drug and is very difﬁcult to control. In the present study, we examined whether
the traditional herbal formulation Shakuyakukanzoto (SKT: 芍藥甘草湯Shao Yao Gan Cǎo Tang) could
relieve oxaliplatin-induced cold dysesthesia in mice. The inhibitory mechanisms were also investigated.
Repetitive administration of SKT (0.1e1.0 g/kg) starting from the day after oxaliplatin injection inhibited
cold dysesthesia in a dose-dependent manner. Our previous report has shown that the mRNA expression
of transient receptor potential melastatin 8 (TRPM8), characterized as a cold-sensing cation channel, is
increased in the dorsal root ganglia of mice treated with oxaliplatin. In addition, TRPM8 antagonist TC-I
2014 (10 and 30 mg/kg) also attenuated cold dysesthesia in oxaliplatin-treated mice. Taken together, it is
suggested that TRPM8 is involved in the cold dysesthesia induced by oxaliplatin. Repetitive adminis-
tration of SKT inhibited the mRNA expression of TRPM8 induced by oxaliplatin in the dorsal root ganglia.
These results suggested that prophylactic repetitive administration of SKT is effective in preventing the
exacerbation of oxaliplatin-induced cold dysesthesia by inhibiting the mRNA expression of TRPM8 in the
dorsal root ganglia.
Copyright © 2016, Center for Food and Biomolecules, National Taiwan University. Production and hosting
by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Oxaliplatin is a third-generation platinum-based chemothera-
peutic drug and is mainly used for the treatment of colorectal
cancer. However, oxaliplatin produces numerous side effects (e.g.,
acute neurotoxicity and chronic peripheral neuropathy) that the
regulation has extremely difﬁcult.1 Although cold dysesthesia is a
characteristic symptom in oxaliplatin-induced peripheral neurop-
athy,2 its underlying mechanisms are not completely understood.
Oxalate, a metabolite of oxaliplatin, has been reported to be
involved in cold dysesthesia.3,4 Our previous report has also been
shown that transient receptor potential melastatin 8 (TRPM8),armacology, Graduate School
f Toyama, Toyama 930-0194,
doh).
for Food and Biomolecules,
molecules, National Taiwan Unive
ons.org/licenses/by-nc-nd/4.0/).characterized as a cold-sensing cation channel5e8 is involved in
oxaliplatin-induced cold dysesthesia.9,10
In oxaliplatin-treated patients, several drugs (e.g., calcium glu-
conate/magnesium sulfate, glutathione, carbamazepine, gaba-
pentin, amifostine, acetyl-L-carnitine and a-lipoic acid) are used for
the management of the peripheral neuropathy.3,11 Although the
above drugs are effective against mild neuropathy,3,11 the regula-
tion is still difﬁcult.
Shakuyakukanzoto (SKT:芍藥甘草湯Shao Yao Gan Cǎo Tang) is a
traditional herbal formulation consisting of two herbal medicines:
Paeoniae Radix (芍藥 Shao Yao) and Glycyrrhizae Radix (甘草 Gan
Cǎo). SKT is effective in treating muscle pain, muscle spasms, joint
pain, and numbness in patients.12e15 In rodents (rats andmice), SKT
inhibits chemotherapy-induced mechanical allodynia.16 However,
it is unknown whether SKT is effective in oxaliplatin-induced cold
dysesthesia. Thus, in this study, we investigated the effects of SKT
on oxaliplatin-induced cold allodynia in mice.rsity. Production and hosting by Elsevier Taiwan LLC. This is an open access article
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2.1. Animals
Male C57BL/6Ncr mice (6 week old at the start of the experi-
ment; Japan SLC Ltd, Hamamatsu, Japan) were used. Five animals
were housed per cage under controlled temperature (21e23 C),
humidity (45e65%), and light (7:00 AM to 7:00 PM) conditions.
Food and water were available ad libitum. Procedures were
approved by the Committee for Animal Experiments at the Uni-
versity of Toyama.2.2. Drugs
Oxaliplatin was purchased from Sigma-Aldrich (St. Louis, MO,
USA) and was dissolved in 5% glucose. Oxaliplatin was injected
intraperitoneally; the dose (3 mg/kg) was selected from our pre-
viously published report17 and was in accordance with the rec-
ommended clinical dose of 85 mg/m2 body surface area, which
corresponds to a dose of 2.4 mg/kg in a person of 170 cm body
height and 60 kg weight. Dried extracts of SKT (Lot. No.
2020068010) were obtained from Tsumura and Co. Ltd (Tokyo,
Japan) and were dissolved in 5% gum arabic. SKT or the vehicle was
administered orally once daily on day 1 and 2 of oxaliplatin injec-
tion. 3-[7-(Triﬂuoromethyl)-5-[2-(triﬂuoromethyl)phenyl]-1H-
benzimidazol-2-yl]-1-oxa-2-azaspiro[4.5]dec-2-ene (TC-I 2014)
(Tocris Bioscience, Bristol, UK) was dissolved in 20% 2-
hdroxypropyl-b-cyclodextrin and was administered orally on day
3 of oxaliplatin injection.18e
2.0 VH2.3. Behavioral experiments for the evaluation of cold dysesthesia
Mice were placed individually in a plastic cage
(110  180  150 mm) with a wire mesh bottom. After an accli-
mation of at least 60 min, acetone (10 ml) was applied to the plantar
skin. The escape response was observed immediately after acetone
application in not only oxaliplatin-treated mice but also healthy
mice. Thus, this response was not evaluated. The reaction following
it was scored as follows: 0, no response; 1, lifting of the hind paw; 2,
ﬂinching or licking of the hind paw. The stimulus was applied 2
times to each hind paw at intervals of more than 20 s, and the
average (total 4 times/mouse) served as a response score.Days after oxaliplatin injeciton
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Fig. 1. Effects of prophylactic Shakuyakukanzoto administration on oxaliplatin-
induced cool dysesthesia in mice. Mice were given an intraperitoneal injection of
oxaliplatin (3 mg/kg) on day 0. Shakuyakukanzoto (SKT) or the vehicle (VH: 5% gum
arabic) was administered orally once daily on day 1 and 2 of oxaliplatin injection. The
evaluation of cold dysesthesia was performed before SKT or VH administration. Data
are presented as mean and standard error of the mean (n ¼ 5). *P < 0.05 compared to
VH (post-hoc Holm-Sidak multiple comparisons).2.4. Reverse transcriptase and polymerase chain reaction (RT-PCR)
The animals were anesthetized with pentobarbital (80 mg/kg,
intraperitoneal) and transcardially perfused with phosphate-
buffered saline (PBS). The dorsal root ganglia (L4eL5 levels) was
removed, immediately frozen in liquid nitrogen, and stored at
80 C until assay. Total RNA was extracted with TRIzol® regent
(Thermo Fisher Sci. Inc., Waltham, MA, USA) and treated with
DNase I (Takara Bio Inc., Shiga, Japan). RT-PCR assay of TRPM8 and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was per-
formed as described.18 The sequences of primers were as follows:
TRPM8, 50-ggctggagatgagattgtgag-30 (sense) and 50-
gctgaagtgggtggagaaga-30 (antisense); glyceraldehyde-3-phosphate
dehydrogenase, 50-ccaaggtcatccatgacaac-30 (sense) and 50-
ttactccttggaggccacgt-30 (antisense). The expression levels of mRNA
were analyzed with NIH Image software (National Institute of
Health, Bethesda, Maryland, USA). The mRNA expression level of
TRPM8 in each sample was normalized to that of GAPDH and was
then further normalized to its expression in the vehicle control.2.5. Statistical analysis
All data are present as the mean and standard error of the mean.
Statistical signiﬁcance was analyzed using two-way repeated
measures analysis of variance (ANOVA) and post hock HolmeSidak
multiple comparisons test or one-way ANOVA and post-hoc Dun-
nett's test. P < 0.05 was considered statistically signiﬁcant.3. Results
3.1. Effects of prophylactic administration of SKT on oxaliplatin-
induced cold dysesthesia
A single intraperitoneal injection of oxaliplatin (3 mg/kg) in-
duces cold dysesthesia, which peaks on day 3.9 Thus, in the present
study, we therefore evaluated the cold dysesthesia until day 3 after
oxaliplatin injection. Repetitive administration of SKT (0.1e1.0 g/
kg) did not affect the initial development of cold dysesthesia after
oxaliplatin administration, but SKT did not signiﬁcantly and dose-
dependently inhibit the exacerbation of the dysesthesia from day
2 after oxaliplatin injection, in comparison with the vehicle (Fig. 1).
Two-way repeated measures ANOVA revealed a signiﬁcant differ-
encewith prophylactic SKT (F3,16¼ 4.292, P < 0.05) and a signiﬁcant
interaction between oxaliplatin treatment and time (F9,48 ¼ 2.344,
P < 0.05).3.2. Effect of TRPM8 antagonist TC-I 2014 on oxaliplatin-induced
cold dysesthesia
Our previous report has shown that the mRNA expression of
TRPM8 in the dorsal root ganglia was observed to peak on day 3
after oxaliplatin injection, and may be involved in oxaliplatin-
induced cold dysesthesia.9,10 Thus, this study examined whether
TRPM8 was involved in oxaliplatin-induced cold dysesthesia using
TRPM8 antagonist TC-I 2014. Oral administration of TRPM8
antagonist TC-I 2014 (10 and 30 mg/kg) inhibited the cold dyses-
thesia in a dose-dependent manner (Fig. 2). Two-way repeated
measures ANOVA revealed a signiﬁcant difference with TC-I 2014
(F2,15 ¼ 8.404, P < 0.01).
Time after injection (h)
0 1 2 3 4 5 6
erocs
esnopser
evisrev
A
0 
0.5 
1.0 
1.5 
2.0 
VH
TC-I 2014 (10 mg/kg)
TC-I 2014 (30 mg/kg)
*
*
*
*
Fig. 2. Effect of TRPM8 TC-I 2014 on oxaliplatin-induced cool dysesthesia in mice. Mice
were given an intraperitoneal injection of oxaliplatin (3 mg/kg) on day 0. TC-I 2014 or
the vehicle (VH: 20% 2-hdroxypropyl-b-cyclodextrin) was administered orally on day 3
of oxaliplatin injection. Following the evaluation of cold dysesthesia was performed
before TC-I 2014 or VH administration, the dysesthesia was evaluated over time after
the administration of them. Data are presented as mean and standard error of the
mean (n ¼ 6). *P < 0.05 compared to VH (post-hoc Holm-Sidak multiple comparisons).
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Fig. 3. Effects of prophylactic Shakuyakukanzoto administration on the expression of
TRPM8 mRNA in the dorsal root ganglia of mice treated with oxaliplatin. Mice were
given an intraperitoneal injection of oxaliplatin (3 mg/kg) on day 0. Shakuyakukanzoto
(SKT) or the vehicle (VH: 5% gum arabic) was administered orally once daily on day 1
and 2 of oxaliplatin injection. The extraction of mRNA on day 3 of oxaliplatin injection
was performed after behavioral evaluation. The mRNA expression level of TRPM8 in
each sample was normalized to that of glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) and further normalized to its expression level in the vehicle control. Upper
panel: a typical example of the mRNA expression levels of TRPM8 and GAPDH. Lower
panel: The mRNA expression level of TRPM8 normalized with GAPDH. Data are pre-
sented as mean and standard error of the mean (n ¼ 5). *P < 0.05 compared to vehicle
(post-hoc Dunnett's test).
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of TRPM8 mRNA in dorsal root ganglia of mice treated with
oxaliplatin
It has been demonstrated that TRPM8 is involved in oxaliplatin-
induced cold dysesthesia based on the present results and our
previous reports.9,10 In addition, single administration of SKT does
not inhibit oxaliplatin-induced cold dysesthesia, suggesting that
SKT does not have the antagonistic activity of TRPM8.19 We
therefore examined the effect of repetitive administration of SKT
(0.1e1.0 g/kg) on the expression of TRPM8 mRNA in the dorsal root
ganglia20 of mice treated with oxaliplatin. Repetitive administra-
tion of SKT (1.0 g/kg) signiﬁcantly inhibited the expression of
TRPM8 mRNA, compared with mice administered the vehicle
(Fig. 3). Although the administration of SKT at higher concentra-
tions (0.3 g/kg) had a tendency to decrease the mRNA expression,
SKT at lower concentrations (0.1 g/kg) did not have that effect
(Fig. 3).4. Discussion
Prophylactic repetitive administration of SKT prevented the
development of cold dysesthesia inmice treatedwith oxaliplatin. In
our preliminary experiments, prophylactic repetitive administra-
tion, but not single administration, inhibited mechanical allodynia
in mice.19 Therefore, SKT would need to be administered repeti-
tively to produce an anti-dysesthesia activity, suggesting that the
regulation of gene expression related in cold dysesthesia is involved
in SKT's mechanism of action.
A single intraperitoneal injection of oxaliplatin increases the
mRNA expression of TRPM8 in the dorsal root ganglia of mice and
peaks at day3 after the injection.9,10 TRP ankyrin 1 (TRPA1) also is
known as a cold-sensing TRP channel.7 TRPM8 and TRPA1 are
activated at temperature below 25 C and 17 C, respectively.7 In
this study, we used acetone for the cold stimulus. In our pre-
liminary experiment, the application of acetone to the plantar skin
decreased the temperature from 28.67 ± 0.10 C to 24.46 ± 0.24 C
(Andoh, Mizoguchi and Kuraishi: unpublished observation). Inaddition to our previous report,10 TRPM8 antagonist TC-I 2014 was
observed to inhibit oxaliplatin-induced cold dysesthesia in mice.
Taken together, TRPM8 is suggested to be involved in the cold
dysesthesia evaluated in this study. However, we do not deny the
involvement of TRPA1 in cold dysesthesia induced by oxaliplatin, as
other recent studies have shown that TRPA1 is involved in
oxaliplatin-induced cold dysesthesia.21,22
TRPM8mRNA is expressed in the dorsal root ganglia, but not the
brain, spinal cord, heart, skin and muscle.6 Repetitive administra-
tion of SKT inhibited the increase of TRPM8mRNA in the dorsal root
ganglia of mice treated with oxaliplatin. However, the inhibitory
mechanisms of SKT on TRPM8 mRNA expression are still unclear.
cAMP response element-binding, c-Myc, myocyte enhancer factor
2, etc. are the reported transcription factors for the regulation of
TRPM8 mRNA expression.23 There are no reports on the regulation
of the above transcription factors by SKT. Hidaka et al.16 have re-
ported that the component Shakuyaku, but not Kanzo, plays an
important role in the regulation of mechanical allodynia. The main
component of Shakuyaku is paeoniﬂorin. Oxaliplatin increases
intracellular Ca2þ ions in primary cultures of dorsal root ganglion
neurons,24 resulting in a greater chance that CREB may be phos-
phorylated and the activate transcription.25 In contrast, paeoni-
ﬂorin inhibits the phosphorylation of CREB26 through the inhibition
T. Andoh et al. / Journal of Traditional and Complementary Medicine 7 (2017) 30e33 33of an increase in intracellular Ca2þ ions.27 In addition, paeoniﬂorin
activates the A1 adenosine receptor, which inhibits the activity of
adenylyl cyclase.28 Thus, the decrease in the concentration of cAMP
induced by paeoniﬂorin may also be involved in the inhibition of
CREB phosphorylation. However, there is no evidence of the regu-
lation of other transcription factors by paeoniﬂorin and other
components of Shakuyaku. These issues will be the focus of our
future study, as SKT may inhibit the mRNA expression of TRPM8
through the regulation of the activation of transcription factors
including CREB.
5. Conclusion
Prophylactic repetitive administration of SKT prevents the
exacerbation of oxaliplatin-induced cold dysesthesia. Thus, SKT
may be useful for the prevention of oxaliplatin-induced peripheral
neuropathy. The underlying mechanism of the anti-cold dyses-
thesia action of SKT may involve the regulation of the expression of
TRPM8.
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